Bavarian Systems and Technologies GmbH
We are developing advanced biotechnological solutions designed to enhance healthcare outcomes. Our diverse and continually evolving portfolio reflects our deep commitment to medical innovation.
About us
Team
Programs
Contact
About us
We are developing advanced biotechnological solutions designed to enhance healthcare outcomes. Our diverse and continually evolving portfolio reflects our deep commitment
to medical innovation.
Our partners are key players in the biotechnology and healthcare industries, including leading research institutions, universities, and innovative startups.
to medical innovation.
Our partners are key players in the biotechnology and healthcare industries, including leading research institutions, universities, and innovative startups.
our programs
We have developed three effective programs that help treat
complex diseases
complex diseases
Androgenetic alopecia & Prostate cancer (androgen receptor gene therapy)
Indication 1: Androgenetic alopecia
Indication 2: androgen-dependent Prostate cancer
Around 50% of men and 30% of women experience some degree of androgenetic alopecia by the age of 50. AR suppression reduces the activity of dihydrotestosterone (DHT), which binds to androgen receptors in hair follicles and leads to hair thinning and eventual hair loss.
Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of cancer-related death worldwide. Around 80–90% of prostate cancers are androgen-dependent. We are developing therapy for suppression of the AR gene expression to slow cancer growth and progression.
Indication 2: androgen-dependent Prostate cancer
Around 50% of men and 30% of women experience some degree of androgenetic alopecia by the age of 50. AR suppression reduces the activity of dihydrotestosterone (DHT), which binds to androgen receptors in hair follicles and leads to hair thinning and eventual hair loss.
Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of cancer-related death worldwide. Around 80–90% of prostate cancers are androgen-dependent. We are developing therapy for suppression of the AR gene expression to slow cancer growth and progression.
Topical Gene therapy downregulating NFKB
inhibitor zeta
inhibitor zeta
Indication: Psoriasis
Description:
Topical gene therapy for downregulating the NFKBIZ (NFKB inhibitor zeta) gene expression to reduce inflammation and keratinocyte proliferation in psoriatic skin.
Around 2-3% of the global population is affected by psoriasis, meaning approximately 125 to 180 million people live with this condition. NFKBIZ is a key participant in skin inflammation pathways, and its expression is elevated in psoriatic skin. Downregulation of the NFKBIZ signaling reduces pro-inflammatory cytokine levels and alleviates psoriasis symptoms.
Description:
Topical gene therapy for downregulating the NFKBIZ (NFKB inhibitor zeta) gene expression to reduce inflammation and keratinocyte proliferation in psoriatic skin.
Around 2-3% of the global population is affected by psoriasis, meaning approximately 125 to 180 million people live with this condition. NFKBIZ is a key participant in skin inflammation pathways, and its expression is elevated in psoriatic skin. Downregulation of the NFKBIZ signaling reduces pro-inflammatory cytokine levels and alleviates psoriasis symptoms.
Next Generation AXL Kinase inhibitors
Indication: various cancers
AXL is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain.
AXL is widely expressed in many organs:
• Macrophages
• Endothelial cells
• Heart
• Liver and skeletal muscle
AXL signaling controls:
• EMT
• Survival
• Motility
• Invasion
• Metastasis development.
AXL is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain.
AXL is widely expressed in many organs:
• Macrophages
• Endothelial cells
• Heart
• Liver and skeletal muscle
AXL signaling controls:
• EMT
• Survival
• Motility
• Invasion
• Metastasis development.
Meet our team
The smartest people work every day to provide the best service and to make our clients happy
-
Boris SurnameDirector -
Petr SurnameDigital marketer and business consultant -
Egor SurnameManager
Contacts
Email:info@nextgenseq.de
Südliche Münchner Str. 19, 82031 Grünwald HRB 214002, Steuernummer 143/122/21234
© ST Bavarian Systems and Technologies GmbH
Androgenetic alopecia & Prostate cancer (androgen receptor gene therapy)
Indication 1: Androgenetic alopecia
Indication 2: androgen-dependent Prostate cancer
Indication 2: androgen-dependent Prostate cancer
Around 50% of men and 30% of women experience some degree of androgenetic alopecia by the age of 50. AR suppression reduces the activity of dihydrotestosterone (DHT), which binds to androgen receptors in hair follicles and leads to hair thinning and eventual hair loss.
Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of cancer-related death worldwide. Around 80–90% of prostate cancers are androgen-dependent. We are developing therapy for suppression of the AR gene expression to slow cancer growth and progression